MARKET

IUGND

IUGND

Imugene
OTCPK
0.0080
NaN%
Closed 09:30 07/10 EDT
OPEN
--
PREV CLOSE
0.010
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.055
52 WEEK LOW
0.0018
MARKET CAP
1.76M
P/E (TTM)
-0.0216
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IUGND last week (0630-0704)?
Weekly Report · 3d ago
Imugene Secures $5.8 Million R&D Tax Refund to Advance Cancer Therapies
TipRanks · 6d ago
Weekly Report: what happened at IUGNF last week (0623-0627)?
Weekly Report · 06/30 10:21
Imugene Initiates Phase II Trial for PD1-Vaxx in Colorectal Cancer
TipRanks · 06/27 00:58
Imugene’s Resolutions Passed at Extraordinary General Meeting
TipRanks · 06/26 02:37
Imugene Advances Cancer Therapy Development with Promising Results
TipRanks · 06/26 01:57
Weekly Report: what happened at IUGNF last week (0616-0620)?
Weekly Report · 06/23 10:17
Imugene Secures US Patent for Oncolytic Virotherapy, Strengthening Global IP Position
TipRanks · 06/18 00:29
More
About IUGND
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Webull offers Imugene Ltd stock information, including OTCPK: IUGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IUGND stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IUGND stock methods without spending real money on the virtual paper trading platform.